Adamis Pharmaceuticals

Its specialty pharmaceutical division currently has four products in its pipeline including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 (Dry Powder Inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. This division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. Adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. Within its biotechnology division, the Company has four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
14 (est)-6%
Adamis Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

Key People/Management at Adamis Pharmaceuticals

Dennis J. Carlo

Dennis J. Carlo

CEO
Robert O. Hopkins

Robert O. Hopkins

CFO

Adamis Pharmaceuticals Office Locations

Adamis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
300 11682 El Camino Real

Adamis Pharmaceuticals Financials and Metrics

Adamis Pharmaceuticals Financials

Adamis Pharmaceuticals's revenue was reported to be $6.5 m in FY, 2016
USD

Revenue (Q3, 2017)

3.4 m

Gross profit (Q3, 2017)

1.3 m

Gross profit margin (Q3, 2017), %

38%

EBIT (Q3, 2017)

(5.8 m)

Market capitalization (13-Dec-2017)

138.6 m

Cash (30-Sep-2017)

23.3 m
Adamis Pharmaceuticals's current market capitalization is $138.6 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

6.5 m

Cost of goods sold

4.9 m

Gross profit

1.6 m

Gross profit Margin, %

25%
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.9 m2.1 m3 m3.8 m3.4 m

Cost of goods sold

1.3 m1.8 m1.7 m1.9 m2.1 m

Gross profit

582.1 k254.5 k1.4 m1.9 m1.3 m

Gross profit Margin, %

30%12%45%51%38%
USDFY, 2014FY, 2015FY, 2016

Cash

5.4 m4.1 m4.1 m

Accounts Receivable

805.4 k

Inventories

14.5 k71 k942.1 k

Current Assets

4.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

119.6 k4.7 m2.1 m5.9 m11.2 m8.5 m6.3 m4.4 m417.1 k7.8 m399.5 k10.7 m23.3 m

Accounts Receivable

744.7 k595.6 k1.2 m1.2 m1 m

Inventories

1.2 m1.1 m914.2 k950 k209.9 k

Current Assets

2.2 m6 m11.3 m8.5 m6.4 m5 m2.6 m10.7 m26.5 m
    USDFY, 2014FY, 2015FY, 2016

    Depreciation and Amortization

    888.4 k2.5 m

    Inventories

    14.5 k(165 k)1.9 k

    Accounts Payable

    671 k116 k(1.7 m)

    Cash From Operating Activities

    5.4 m306 k
    USDQ1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Depreciation and Amortization

    2.3 m

    Accounts Receivable

    744.7 k595.6 k1.2 m1 m

    Inventories

    1.2 m914.2 k209.9 k

    Accounts Payable

    547.7 k750 k977.2 k498 k408.8 k1.5 m4.2 m1.7 m2.7 m1.8 m
      Y, 2017

      Financial Leverage

      1.2 x
      Show all financial metrics

      Adamis Pharmaceuticals Market Value History

      Adamis Pharmaceuticals's Web-traffic and Trends

      Adamis Pharmaceuticals Company Life and Culture

      You may also be interested in